Pfizer Intangible Assets

Pfizer's intangible assets stands at $47B as of June 2026. That compares with $53B in the prior-year period — down 10.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Pfizer reported $47B in intangible assets versus $53B a year earlier — a 10.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $53B in the prior-year period — down 10.7% year over year. Sustained growth in intangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Pfizer's intangible assets evolved across reporting periods, while the comparison chart places PFE.DE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, intangible assets is commonly used to spot outliers. Pfizer's reading of $47B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.